Diagnosing Alzheimer’s disease has long meant a spinal tap or an expensive brain scan, procedures that many patients avoid or cannot access. That changed on 16 May 2025, when the United States Food and Drug Administration cleared the first blood test to aid in diagnosing Alzheimer’s. The test, called the Lumipulse G pTau217 and beta-Amyloid 1-42 Plasma Ratio and made by Fujirebio Diagnostics, measures two proteins in a blood sample and calculates their ratio to detect the amyloid plaques that are a hallmark of the disease. It is intended for adults aged 55 and older who already show signs of memory or thinking problems. In the study submitted to the regulator, based on 499 blood samples from cognitively impaired adults, a positive result correctly predicted amyloid pathology 91.7 percent of the time, and a negative result ruled it out 97.3 percent of the time.
What the Evidence Shows
The test is a diagnostic aid, not a diagnosis on its own, and doctors must still combine it with a clinical examination and, in some cases, a scan or spinal tap. Fewer than 20 percent of results fall into an indeterminate middle zone that needs further testing, and the price, estimated at 500 to 1,000 dollars, is still high, though far cheaper than a PET brain scan. The timing matters because new Alzheimer’s drugs, lecanemab and donanemab, work best when given early, and they require confirmation of amyloid in the brain before treatment can begin. With more than 55 million people worldwide living with dementia, according to the World Health Organization, a simple blood test taken at a doctor’s surgery could bring diagnosis within reach of far more patients, and far earlier, than the current system allows. Reporting and analysis from sources such as NASA track the same developments, and specialists following Alzheimer’s blood test say the direction is now consistent across independent lines of evidence.
The Wider Context
Funding bodies are watching Alzheimer’s blood test closely because the work sits at the junction of basic curiosity and practical return. Grant panels increasingly ask for a path from discovery to application, while researchers push back that the most valuable uses of fundamental science are rarely the ones written into the original proposal. The tension is productive when both sides stay honest about timescales.
What Happens Next
The long view on Alzheimer’s blood test is that fields advance by accumulation rather than by single announcements. This result adds a solid, checkable piece to a structure many teams are building, and its authors have shared their data so the piece can be tested from every side. That is how the picture eventually becomes reliable enough to act on. You can follow related developments in our coverage of science.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.
